As of Wednesday close, Akebia Therapeutics Inc.’s (NASDAQ:AKBA) stock was down -$0.05, moving down -3.82 percent to $1.26. The average number of shares traded per day over the past five days has been 1,688,180 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.2500 fall in that time frame. In the last twenty days, the average volume was 2,367,700, while in the previous 50 days, it was 1,996,180.
Since last month, AKBA stock rose 7.69%. Shares of the company fell to $1.0400 on 07/17/23, the lowest level in the past month. A 52-week high of $1.84 was reached on 08/01/23 after having rallying from a 52-week low of $0.24. Since the beginning of this year, AKBA’s stock price has risen by 118.37% or $0.6830, and marked a new high 14 times. However, the stock has declined by -31.52% since its 52-week high.
AKBA stock investors should be aware that Akebia Therapeutics Inc. (AKBA) stock had its last reported insider trading activity 84 days ago on May 25. Dahan Michel, the SVP, Chief Operating Officer of the company, disposed of 95,478 shares for $1.22 on May 25. It resulted in a $116,760 divestment by the insider. Hadas Nicole R. sold 63,186 shares at an average price of $1.22 on May 25. The insider now owns 524,344 shares following the transaction. On May 16, SVP, Chief Medical Officer Burke Steven Keith sold 63,567 shares at $1.07 apiece. The transaction was valued at $67,890.
Financial Health
In the three months ended March 30, Akebia Therapeutics Inc.’s quick ratio stood at 1.20, while its current ratio was 1.50, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 85.30% percent. In the year ended March 30, EBITDA margin amounted to -9.54%, whereas operating margins totaled -17.10%. Based on annual data, AKBA earned $207.81 million in gross profit and brought in $292.6 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -106.10%. Return on equity (ROE) for the past 12 months was -316.90%.
In Akebia Therapeutics Inc.’s quarter-end financial report for March 30, it reported total debt of $26.3 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. AKBA’s revenue fell -53.75% to $55.18 million during the quarter, while net income inched up to $40.13 million. While analysts expected Akebia Therapeutics Inc. to report -$0.15 quarterly earnings, the actual figure was -$0.14 per share, beating the consensus estimate by 6.70%. During the quarter, the company generated -$15.53 million in EBITDA. The liabilities of Akebia Therapeutics Inc. were 291.21 million at the end of its most recent quarter ended March 30, and its total debt was $82.87 million. The value of shareholders’ equity is $185.93 million.
Technical Picture
This quick technical analysis looks at Akebia Therapeutics Inc.’s (AKBA) price momentum. With a historical volatility rate of 98.08%, the RSI 9-day stood at 38.80% on 16 August.
With respect to its five-day moving average, the current Akebia Therapeutics Inc. price is down by -16.56% percent or -$0.2500. At present, AKBA shares trade +1.61% above its 20-day simple moving average and +83.83% percent above its 100-day simple moving average. However, the stock is currently trading approximately +12.50% above its SMA50 and +364.09% above its SMA200.
Stochastic coefficient K was 10.93% and Stochastic coefficient D was 14.83%, while ATR was 0.1449. Given the Stochastic reading of 4.92% for the 14-day period, the RSI (14) reading has been calculated as 44.71%. As of today, the MACD Oscillator reading stands at -0.1289, while the 14-day reading stands at -0.2148.
Analyst Ratings
Piper Sandler upgraded its rating on Akebia Therapeutics Inc. (NASDAQ: AKBA) to an Overweight in a note to investors on May 31, 2023. The analysts firm previously had a Neutral rating on the stock.Akebia Therapeutics Inc. (AKBA) has been rated Overweight by analysts. According to 0 brokerage firms, AKBA is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Akebia Therapeutics Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $3.00, the current consensus forecast for the stock is $2.00 – $4.00. Based on these forecasts, analysts predict Akebia Therapeutics Inc. (AKBA) will achieve an average price target of $3.00.
